EVOLVE-2: galcanezumab effective for episodic migraine

  • Skljarevski V & al.
  • Cephalalgia
  • 1 Jan 2018

  • curated by Kelli Whitlock Burton
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Galcanezumab significantly reduced the number of mean monthly migraine headache days (MHDs) in patients with episodic migraine compared with placebo, according to results of the EVOLVE-2 international randomized phase 3 trial.
  • Both once-monthly dosages of 120 and 240 mg were effective, and both resulted in a decrease in use of acute migraine medications.

Why this matters

  • These results are similar to a companion phase 3 trial, EVOLVE-1.
  • Nearly 70% of people who receive preventive therapy for episodic migraines stop taking the medication within 6 months because of ineffectiveness or intolerability.

Study design

  • Randomized clinical trial of 915 patients (galcanezumab 120 mg, n=231; 240 mg, n=223; placebo, n=461) with episodic migraine between January 2016 and March 2017.
  • Funding: Eli Lilly and Company.

Key results

  • Mean monthly MHDs were significantly reduced by 2.02 days for galcanezumab 120 mg and 1.90 days for 240 mg vs placebo.
  • Significant number of patients in galcanezumab 120 and 240 mg groups experienced ≥50%, ≥75%, and 100% reduction in MHDs vs placebo (P<.001 for all>
  • Treatment with both 120 and 240 mg galcanezumab was associated with a significant decrease in the days of use of acute migraine medications.

Limitations

  • Patients with serious medical conditions were excluded.

Coauthored with Anand Ramanathan, PharmD

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit